Table 2 Comparison of biomarkers between patients and controls during the three disease progression phases
Viral phase (1–9 days) | Patients N = 93 | Controls N = 55 | p-value |
|---|---|---|---|
IL-8 (pg/mL) | 50.31 [34.62; 69.05] | 56.21 [43.26; 107.75] | 0.025 |
G-CSF (pg/mL) | 138.42 [120.43; 159.45] | 130.47 [124.32; 138.97] | 0.032 |
MPO-DNA | 0.75 [0.63; 0.95] | 0.52 [0.43; 0.72] | < 0.001 |
NE-DNA | 1.06 [0.87; 1.25] | 0.72 [0.60; 0.89] | < 0.001 |
cfDNA (ng/mL) | 6.67 [4.04; 13.69] | 2.56 [1.71; 3.61] | < 0.001 |
CitH3 (ng/mL) | 23.35 [11.32; 34.99] | 20.91 [15.92; 31.94] | 0.599 |
Early inflammation (10–16 days) | Patients N = 59 | Controls N = 55 | p-value |
|---|---|---|---|
IL-8 (pg/mL) | 55.02 [42.51; 88.89] | 56.21 [43.26; 107.75] | 0.725 |
G-CSF (pg/mL) | 146.39 [129.14; 162.05] | 130.47 [124.32; 138.97] | 0.001 |
MPO-DNA | 0.90 [0.64; 1.10] | 0.52 [0.43; 0.72] | < 0.001 |
NE-DNA | 1.03 [0.87; 1.25] | 0.72 [0.60; 0.89] | < 0.001 |
cfDNA (ng/mL) | 7.51 [5.04; 11.66] | 2.56 [1.71; 3.61] | < 0.001 |
CitH3 (ng/mL) | 35.89 [21.49; 68.04] | 20.91 [15.92; 31.94] | 0.003 |
Late inflammation (> 16 days) | Patients N = 45 | Controls N = 55 | p-value |
|---|---|---|---|
IL-8 (pg/mL) | 78.18 [50.36; 111.21] | 56.21 [43.26; 107.75] | 0.093 |
G-CSF (pg/mL) | 149.48 [132.43;157.64] | 130.47 [124.32; 138.97] | < 0.001 |
MPO-DNA | 0.87 [0.74; 1.05] | 0.52 [0.43; 0.72] | < 0.001 |
NE-DNA | 1.00 [0.88; 1.32] | 0.72 [0.60; 0.89] | < 0.001 |
cfDNA (ng/mL) | 11.24 [5.77; 17.77] | 2.56 [1.71;3.61] | < 0.001 |
CitH3 (ng/mL) | 54.54 [28.72; 89.53] | 20.91 [15.92; 31.94] | < 0.001 |